Smoking Cessation Market By Product (Nicotine Replacement Therapy, Drug Therapy, E-cigarettes) Regional Analysis & Forecast - 2026

Introduction

Smoking cessations are drugs and therapies used in the treatment of withdrawal symptoms associated with the cessation of nicotine. Nicotine use is a risk factor for many diseases and disorders including cardiovascular diseases, cancer, etc. Green tobacco sickness, caused by nicotine absorption through the skin by the handling of wet tobacco leaves in the tobacco industry is also a concern especially among children. Awareness about these health hazards has influenced individuals to adopt smoking cessation therapy. Awareness through television advertisements, information brochures, newspapers, and other media has proved to be effective in curbing the nicotine addiction crisis to some extent.

Market Overview

The global smoking cessation market is expected to reach over USD xx billion by 2026. The other market driving factors include increasing desire and drives to quit smoking and active role of social and health organizations against tobacco use, the prohibitive costs due to high taxes leveraged on tobacco products, social stigma imposed on tobacco users, etc. The other critical market-driving factor is the huge number of unmet needs. The World Health Organization (WHO), estimates around 1,100 million smokers worldwide with emerging economies accounting for about 70% of the global smoker population.

Currently, the FDA has approved numerous NRT products, as well as other prescription drugs, for smoking cessation.  Specifically, the FDA has approved three types of over-the-counter NRTs–nicotine gum, transdermal nicotine patch, and nicotine lozenge, and two types of prescription NRTs-nicotine nasal spray and nicotine inhaler. There are no products of electronic nicotine delivery system (ENDS) currently approved for use as an NRT for smoking cessation.  ENDSs available today, including e-cigarettes and personal vaporizers, are marketed only for recreational use and thus are regulated by FDA as tobacco products.  ENDS marketing as a smoking cessation tool with smoking cessation claims has to require FDA premarket approval as a “drug.”

The increase in the desire to quit smoking and the numerous health complications associated with smoking act as strong incentives for companies for introducing novel smoking cessation products, such as Revolymer, which has entered the next generation nicotine gums for helping smokers to quit smoking. The launching of these improved and innovative nicotine replacement therapy products is to serve as an important impact-rendering driver for the growth of the smoking cessation market.

The growth in the incidence of target diseases like chronic obstructive pulmonary disease (COPD), asthma, cardiac diseases, and lung cancer, and the increasing awareness about the hazardous side effects of smoking are the factors anticipated to promote the expansion of the market. Educational institutions are remaining active in organizing various campaigns and programs to spread information about the harmful effects and consequences of smoking to increase young population awareness. The market players are showing slow and steady progress in the e-cigarette market by keeping the focus on developing, commercializing, and distributing the nicotine products that are FDA approved. For example, in 2014, Victory Electronic Cigarettes Corporation acquired Ten Motives Ltd. with an aim to expand its distribution channels and attain broader market coverage.

Key Developments

• In March 2019, FDA Released the second draft guidance to support the development of novel nicotine replacement therapies.


• In March 2019, Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, is up 83% premarket on robust volume following its update on smoking cessation med cytisinicline.

Segmentation

The global smoking cessation market is segmented on the basis of Product and Region.

Based on the product:

• Nicotine Replacement Therapy: Nicotine Spray, Nicotine Gum, Nicotine Transdermal Patches, Nicotine Inhalers, Nicotine Sublingual Tablets, and Nicotine Lozenges.


• Drug Therapy: Varenicline, Zyban, Nicorette Buccal


• E-cigarettes

Nicotine Replacement Therapy (NRT) is dominating the smoking cessation market owing to Increased availability and the introduction of the ingestible nicotine products having different flavors. The e-cigarette segment is expected to grow at a significant rate over the forecast period owing to introducing second and third generation e-cigarettes, the presence of numerous vendors operating and selling e-cigarettes under different brand names, and the availability of various flavored products.

Based on the region: North America, Europe, Asia Pacific, Latin America, and MEA.

North America holds the largest market share due to the increasing awareness levels of various products for, e.g. around 90% of the U.S. population was identified as aware of e-cigarettes. The Asia Pacific is known to be the fastest growing market. The registration of novel products and e-cigarettes, and the strengthening of the company distribution channels in countries, including China, India, and Australia, are anticipated for the market growth over the forecast period.

The key players of Global smoking cessation market include Pfizer, Inc., Cipla Ltd., Novartis International AG, Takeda Pharmaceutical Company Ltd., McNeil AB, GlaxoSmithKline plc, Imperial Tobacco Ltd., Revolymer plc, VMR Products, LLC, and others.